# Study to Evaluate Safety and Clinical Activity of AB122 in Biomarker Selected Participants With Advanced Solid Tumors

> **NCT04087018** · PHASE1 · COMPLETED · sponsor: **Arcus Biosciences, Inc.** · enrollment: 18 (actual)

## Conditions studied

- Advanced Solid Tumors

## Interventions

- **DRUG:** zimberelimab

## Key facts

- **NCT ID:** NCT04087018
- **Lead sponsor:** Arcus Biosciences, Inc.
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2019-09-24
- **Primary completion:** 2024-06-17
- **Final completion:** 2024-06-17
- **Target enrollment:** 18 (ACTUAL)
- **Last updated:** 2024-09-19

## Collaborators

- [object Object]
- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT04087018

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT04087018, "Study to Evaluate Safety and Clinical Activity of AB122 in Biomarker Selected Participants With Advanced Solid Tumors". Retrieved via AI Analytics 2026-05-25 from https://api.ai-analytics.org/clinical/NCT04087018. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*